Toxoplasma RAP Domain Antigen for Diagnostic Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for Toxoplasma gondii infection, particularly for detecting anti-T. gondii IgM, lack sensitivity and specificity, and there is a need for improved vaccines and treatments, especially for congenital toxoplasmosis.
Innovation Solution
The use of a T. gondii RAP domain-containing protein, significantly induced in vivo, as a diagnostic marker and potential vaccine candidate, which can detect specific IgM antibodies and aid in the development of more effective treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic tests are used to detect anti-T. gondii IgM, then the testing process can be performed, but the sensitivity and specificity are insufficient
Solution Approach 1:
The patent changes the antigenic parameters by using in vivo-induced antigens (IVIA) instead of conventional in vitro antigens. This parameter change results in antigens that are more representative of actual infection conditions, thereby improving both sensitivity and specificity of IgM detection. The in vivo-induced antigens exhibit different molecular weight profiles and immunogenic properties compared to conventional antigens, leading to enhanced diagnostic accuracy.
2Measurement precision
If in vivo-induced antigens are used for diagnosis, then sensitivity and specificity improve, but the complexity of antigen preparation increases
Solution Approach 1:
The patent segments the antigen preparation process into distinct stages: in vitro cultivation of T. gondii, in vivo induction in animal models, extraction of induced antigens, and purification. This segmentation allows for systematic optimization of each step and facilitates the development of standardized protocols. The segmented approach also enables independent validation of each preparation stage, reducing overall process complexity.
Solution Approach 2:
The patent performs preliminary identification and characterization of in vivo-induced antigens before applying them in diagnostic tests. This preliminary action includes profiling the antigenic repertoire, selecting candidate antigens with high immunogenicity, and validating their specificity. By performing these actions in advance, the patent simplifies the subsequent diagnostic application and ensures high performance without requiring complex real-time adjustments.
3Reliability
If conventional vaccines are used against Toxoplasma, then vaccination can be administered, but efficacy against congenital toxoplasmosis is limited
Solution Approach 1:
The patent changes the vaccine antigen parameters by utilizing in vivo-induced antigens that mimic the actual infection scenario more closely. This parameter change enhances the immune response quality, producing antibodies and cellular immunity that are more effective against congenital transmission. The in vivo-induced antigens stimulate a broader and more robust immune response compared to conventional vaccines, thereby improving protective efficacy.
4Ease of operation
If standard diagnostic procedures are followed, then the diagnostic workflow can be maintained, but the ability to detect acute infection is reduced
Solution Approach 1:
The patent introduces in vivo-induced antigens as intermediaries between the diagnostic system and the target antibodies. These intermediary antigens serve as superior recognition targets compared to conventional antigens, enabling more accurate detection of acute infections. The intermediary antigens bridge the gap between simple diagnostic workflows and high detection precision by providing enhanced epitope recognition while maintaining procedural simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The T. gondii RAP domain-containing protein demonstrates high sensitivity and specificity for detecting T. gondii-specific IgM, offering a promising diagnostic tool and potential therapeutic target, and could improve vaccine efficacy against toxoplasmosis.
Implementation Method 1
detecting specific and selective antigen-antibody binding, wherein the binding indicates the presence of T. gondii-specific antibodies present in the test sample
Data Source
AI summary
The present invention relates to methods of screening biological samples for the presence of T. gondii. More particularly, the present invention relates to a sensitive and specific screening test for the presence of Toxoplasmosis in subjects by using or detecting the in vivo-induced T. gondii RAP domain binding protein antigen. The invention further relates to the use of the in vivo-induced antigen in the prevention or therapy of Toxoplasmosis.